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OBJECTIVES This study aimed to determine whether nitroglycerin (NTG) treatment affects matrix
metalloproteinase (MMP) gene expression and activities in human macrophages.
BACKGROUND Nitroglycerin is one of the most frequently used therapeutic agents for the symptomatic relief
of stable or unstable coronary artery disease; however, its effects on vascular biology are poorly
characterized. Despite its powerful vasodilator activity, NTG has not been shown to improve
outcomes in coronary disease. We now describe evidence that NTG has potentially
pro-inflammatory effects in human monocyte-derived macrophages (MDMs).
METHODS Human monocytes were isolated from whole blood by elutriation and allowed to differentiate
into macrophages over eight to 10 days. The MDMs were then treated for 4 or 24 h with
control media, pharmacologically relevant doses of NTG or other nitric oxide donors. Matrix
metalloproteinase activity was measured by zymography, protein levels measured by enzyme-
linked immunosorbent assay and messenger ribonucleic acid (mRNA) levels were quantified
by competitive reverse transcription-polymerase chain reaction.
RESULTS The major MMP expressed by MDMs was MMP-9. Nitroglycerin treatment stimulated a
dose-dependent increase in MMP-9 mRNA levels (NTG 200 pmol: 193  6% and NTG
2,000 pmol: 372  9% compared to controls, p  0.005) and MMP-9 activity (NTG 200:
142  5.5% and NTG 2,000: 167  11% compared to controls, p  0.005). Nitroglycerin
2,000 pmol also increased MMP-2 and MMP-7 mRNA levels to 187  8% and 183  21%
of control values, respectively (p  0.05). Furthermore, tissue inhibitor of metalloproteinase
(TIMP)-1 (the major tissue inhibitor of MMPs) mRNA and protein levels were decreased in
NTG 2,000 pmol-treated MDMs compared with control cells (mRNA: 67 7%, p 0.005;
protein: 45  5%, p  0.005).
CONCLUSIONS Nitroglycerin in pharmacologically relevant concentrations activates MMP but represses
TIMP expression in human macrophages. The subsequent imbalance in MMP/TIMP
expression associated with NTG treatment could promote matrix degradation, with poten-
tially adverse effects on plaque stability. (J Am Coll Cardiol 2002;39:1943–50) © 2002 by
the American College of Cardiology Foundation
Nitroglycerin (NTG) is one of the most frequently used
therapeutic agents for the symptomatic relief of stable or
unstable coronary artery disease (CAD), having first been
used for this purpose in 1879 (1). Nitroglycerin releases
nitric oxide (NO) within smooth muscle cells, leading to
vasorelaxation. Despite this, there have been no reports that
NTG attenuates the progression of atherosclerosis or pro-
vides prognostic benefit in subjects with coronary disease; in
fact, in acute coronary syndromes, nitrates do not improve
outcomes, despite their coronary vasodilator effects (2,3).
This may be due to reported limitations of NO donors,
including the requirement for biotransformation, nitrate
tolerance and/or the release of superoxide when NTG is
given in vivo (4). We now report, however, that at plasma
concentrations of NTG observed after in vivo treatment,
this NO donor may have significant pro-inflammatory
effects on monocyte-derived macrophages (MDMs), a key
cell type in atherosclerosis. As MDM release of matrix
degrading proteases has been implicated in plaque instabil-
ity (5,6), these observations may suggest a potentially
deleterious effect of NTG in patients with CAD.
Atherosclerosis is characterized by the formation of
arterial plaques consisting of a lipid core with a fibrous cap.
The mechanical strength of the plaque cap is a vital
component of plaque stability and depends (in part) on the
amount of matrix proteins (7). The cap tissue is dynamic,
with synthesis of matrix proteins by cells being balanced by
degradation of the matrix. A range of proteases, including
the metalloproteinases, performs matrix degradation. Met-
alloproteinases are multidomain, zinc-containing neutral
endopeptidases and include the collagenases, stromelysins,
gelatinases and membrane-type metalloproteinases (7). The
major matrix metalloproteinase (MMP) expressed by mac-
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rophages is the gelatinase MMP-9 (8). Plaque macrophages
also express increased levels of MMP-1, MMP-2, MMP-3
and MMP-7 compared with normal arterial tissue, as
demonstrated by in situ hybridization or immunohisto-
chemistry (9,10).
Metalloproteinases are powerful enzymes, and as such
their activity is tightly regulated. Regulation occurs at
several levels, including gene expression, secretion of pro-
enzymes that require activation and inhibition by tissue
inhibitors of metalloproteinases (TIMPs), chiefly TIMP-1
(7). Metalloproteinases are not constitutively expressed in
most cell types; rather, gene transcription is induced by a
variety of factors including growth factors and cytokines.
Importantly, MMP expression and activity can be modu-
lated by reactive oxygen species and NO (11). Therefore, we
investigated whether NTG affected MMP and TIMP levels
in human MDMs.
METHODS
Isolation of human monocytes and culture of human
MDMs. White cell concentrates were obtained from the
peripheral blood of healthy human volunteers and mono-
cytes were removed within 24 h of collection by density
gradient separation of the white cells on Lymphoprep
(Nycomed Pharma, Asker, Norway) followed by counter-
flow centrifugation elutriation at 20°C, as previously de-
scribed by our group (12), by use of a Beckman J2-21 M/E
centrifuge equipped with a JE-6B elutriation rotor and a
4.2 ml elutriation chamber (Beckman Coulter Inc., Fuller-
ton, California). The elutriation buffer was Hanks buffered
saline solution without calcium or magnesium (Sigma-
Aldrich, Castle Hill, NSW, Australia), supplemented with
ethylenediaminetetra-acetic acid (0.1 g/l) and 1% heat-
inactivated human serum. The system and tubing were
rinsed with 250 ml each of 70% ethanol, endotoxin-free
water, 6% hydrogen peroxide, endotoxin-free water and
elutriation buffer in that order before the Lymphoprep-
derived mononuclear cell fraction was loaded at 9 ml/min
into the elutriation rotor chamber (2,020 rpm at 20°C).
Flow rate was increased by 1 ml/min increments every
10 min, and monocytes were typically eluted at between 16
and 17 ml/min. Collected fractions were examined by a
Cytospin system (Thermo Trace Scientific, Melbourne, Vic,
Australia) and Wright’s stain (Diff-Quik, American Scien-
tific Products, McGaw, Illinois). Monocyte purity of 90%
and viability of 95% by Trypan blue exclusion were
confirmed on light microscopy, and the monocytes were
resuspended in RPMI (Life Technologies, Melbourne, Vic,
Australia), plated onto 12-well tissue culture plates and
allowed to adhere for 1.5 h at 37°C under 5% CO2 in air.
The medium was then removed and the adherent mono-
cytes washed twice gently with 1X phosphate-buffered
saline before adding RPMI containing 10% human serum,
penicillin G (50 U/ml) and streptomycin (50 fg/ml).
Media changes occurred every two to three days. On days
8 to 10, cells were treated for 4 or 24 h with NTG (200
and 2,000 pmol; Saphire Bioscience Pty Ltd., Sydney,
Australia), 3-morpholinosydnoimine hydrochloride
(2,000 pmol; Saphire Bioscience Pty Ltd.), S-nitroso-N-
acetylopenicillamine (2,000 pmol; Saphire Bioscience Pty
Ltd.) or glycerol (GLY) (200 and 2,000 pmol). Untreated
cells acted as controls. The concentrations of NTG were
chosen to span the range of concentrations usually seen in
vivo in plasma, after NTG administration to humans by the
sublingual, transdermal or intravenous routes for the treat-
ment of CAD (13–16). Each experiment was performed at
least three times, with triplicate wells for each condition.
RNA isolation and competitive reverse transcription-
polymerase chain reaction (RT-PCR) protocol. Total
ribonucleic acid (RNA) was extracted using TRI reagent
(Sigma), normalized to 250 ng/l by the SYBR Green II
nucleic acid stain assay (17) and stored at 70°C. Com-
petitive RT-PCR was performed on the total RNA
samples. The protocol is based on multitemplate RNA
competitor molecules and has previously been described
by our group (18). The competitive RT-PCR protocol
involved c-deoxyribonucleic acid synthesis in 10 l volumes
containing 250 ng of total RNA and 1:2 serial dilutions of
the RNA competitor molecule in standard Superscript II
RNaseH- reverse transcriptase reactions (Life Technolo-
gies). The reactions were incubated at 25°C for 5 min, 50°C
for 30 min and 94°C for 2 min. Polymerase chain reaction
amplification was performed in 25 l reaction volumes
containing 10% of the reverse transcription reaction, 1X
polymerase chain reaction buffer (PE Biosystems, Foster
City, California), 0.2 mM deoxynucleotide triphosphate
(Boehringher Mannheim Australia, Castle Hill, Australia),
20 pmol of sense and antisense primers and 2.5 U Taq
polymerase (PE Biosystems). The temperature cycling pro-
file was as follows: 94°C for 15 s, 55°C for 20 s, 72°C for
45 s; this profile was cycled 25 times for beta-actin, 30 times
for TIMP-1 and MMP-9 and 35 times for MMP-7 and
MMP-2 in a Perkin-Elmer 9600 thermal cycler (Wellesley,
Massachusetts). Primer sequences for MMP-2 were sense
Abbreviations and Acronyms
AP-1  activator protein-1
APMA  p-aminophenyl mercuric acetate
CAD  coronary artery disease
GLY  glycerol
MDM  monocyte-derived macrophage
MMP  metalloproteinase
mRNA  messenger ribonucleic acid
NF-B  nuclear factor-kappa B
NO  nitric oxide
NTG  nitroglycerin
RNA  ribonucleic acid
ROS  reactive oxygen species
RT-PCR  reverse transcription-polymerase chain
reaction
SDS-PAGE  sodium dodecyl sulfate-polyacrylamide gels
TIMP  tissue inhibitors of metalloproteinase
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5 CGC CGT CGC CCA TCA TCA AGT and antisense
5 TGG ATT CGA GAA AAC CGC AGT GG (19).
The sequences for MMP-7 were sense 5 AGA TGT GGA
GTG CCA GAT GT and antisense 5 TAG ACT GCT
ACC ATC CGT CC (20). The MMP-9 and TIMP-1
sequences have been described by our group (18).
Polymerase chain reaction products were separated on 2%
agarose gels containing 50 ng/ml ethidium bromide and the
image was directly digitized (Grab-It; UVP Ltd., Cam-
bridge, United Kingdom). The band densities were mea-
sured using Phoretix software (Phoretix International, New-
castle Upon Tyne, United Kingdom) and normalized on the
basis of the molecular weight of the product (21). The log of
the ratio of the band densities within each lane was plotted
against the log of the concentration of RNA competitor
molecule added per reaction. The concentration of the
target messenger ribonucleic acid (mRNA) was determined
where the ratio of the competitor and target band densities
was equal to 1.
TIMP-1 protein concentrations. TIMP-1 protein con-
centrations in the conditioned media were determined by
commercially available enzyme-linked immunosorbent as-
says (Amersham Pharmacia Biotech, Castle Hill, Sydney,
Australia).
Zymography. Sodium dodecyl sulfate-polyacrylamide gels
(SDS-PAGE) containing gelatin (1 mg/ml) were used to
demonstrate gelatinolytic activity (22) in conditioned media
from MDM cell cultures. Conditioned media was normal-
ized to 15 g or 4.5 g total protein concentration before
electrophoresis. Dilution to 4.5 g was necessary to obtain
optimal band resolution for densitometric analysis. Total
protein concentration was determined by a commercially
available BCA method (BioRad, Sydney, Australia). For
electrophoresis, 20 l of sample was loaded onto 8  10 cm
(SDS-PAGE) containing 1 mg/ml of gelatin under nonre-
ducing conditions. The gels were run at 100 V for 45 min.
Molecular weight standard proteins (BioRad, Regents Park,
NSW, Australia) were run simultaneously. After SDS-
PAGE, the gels were washed twice in 2.5% Triton X-100
(2 15 min) to remove sodium dodecyl sulfate from the gel
and then incubated for 4 h at 37°C in 50 mM Tris-HCl,
pH 7.4, containing 10 mM calcium chloride and 0.05% Brij
35 (Sigma). After incubation, the gels were stained in a
solution of 0.25% Coomassie blue in methanol:acetic acid:
water (30:10:60, v/v/v) and then destained in methanol:
acetic acid:water (30:10:60, v/v/v) until clear bands were
observed against the blue background of stained gelatin.
The gels were digitized directly (Grab-It software, UVP
Ltd., Cambridge, United Kingdom), and the intensity of
the bands was measured using Phoretix software (Phoretix
International).
It has been demonstrated that activation of MMPs can be
elicited by p-aminophenyl mercuric acetate (APMA) treat-
ment. To see fully active MMP-9, aliquots of some samples
were incubated with APMA (1 mM, 37°C, 30 min) to
cleave the proenzyme for maximal MMP zymographic
activity. After activation, the samples were subjected to
zymographic analysis as previously described.
Data analysis. Results of the experimental studies are
reported as mean  SEM compared with control condi-
tions. Analysis of variance was used for statistical analysis
with Scheffe’s test for post-hoc pairwise comparison. A p
value of 0.05 was regarded as significant.
RESULTS
Effect of NTG exposure on MMP-9 protein levels in
human MDMs. Zymographic analysis of conditioned me-
dia from cultured human MDMs showed that the major
gelatinase secreted by the human MDMs was MMP-9 (Fig.
1A; clear band at 90 kDa). When 15 g total protein was
analyzed by zymography, both the latent (heavier band) and
active (lighter band) forms of MMP-9 were observed. No
MMP-2 activity (clear band at70 kDa) could be detected.
Macrophages exposed to NTG 200 pmol for 24 h (Fig. 1A;
Lanes 3 and 4) showed more latent and active MMP-9
activity then cells exposed to equimolar concentrations of
GLY (Lanes 1 and 2).
Figure 1B shows recruitable MMP-9 activity present in
the MDM samples. These samples were activated in vitro
via APMA treatment, and the large clear bands indicate
there is abundant MMP-9 activity present in these samples.
Incubation of MDMs with NTG 200 pmol for 24 h
increased recruitable MMP-9 activity compared to GLY-
treated controls (Lanes 3 and 4 vs. Lanes 1 and 2; Fig. 1B).
To quantify differences in MMP-9 levels, samples were
diluted to 4.5 g and cells were exposed to NTG for only
4 h in order to obtain optimal band resolution. Figure 2
shows that incubation of MDMs with NTG (200 and
2,000 pmol) increased the intensity of the MMP-9 band,
migrating at 90 kDa (NTG 200, 142  5.5%; NTG
2,000, 167  11% compared to control, 100  1.34%; p 
0.005 or p  0.001, respectively). Administration of other
NO donors, SIN-1 (200 pmol) and SNAP (200 pmol), also
resulted in an increase in MMP-9 activity (134  6% and
123  5.4%, p  0.05 and NS, respectively). Treatment of
cells with GLY (same chemical background as NTG) did
not increase MMP-9 activity (gly 200, 79  8.3%; gly
2,000, 102  6.5% compared to control, p  NS).
NTG increases MMP-9 mRNA levels in human
MDMs. Matrix metalloproteinase-9 mRNA levels were
measured by competitive RT-PCR using a MMP-9 specific
heterologous RNA template (18). This assay showed that a
4-h exposure of MDMs to 200- or 2,000- pmol NTG
increased MMP-9 mRNA levels in a concentration depen-
dent manner. Figure 3 shows NTG 200 pmol increased
MMP-9 mRNA levels to 193 6% of control levels (100
7.5%, p  0.0005). Nitroglycerin 2,000 pmol caused a
further induction to 372  9% (p  0.0001).
NTG increases MMP-2 and MMP-7 mRNA levels in
human MDMs. To determine whether NTG induced
other MMPs at the mRNA level in human MDMs,
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MMP-2 and MMP-7 mRNA levels were also measured by
competitive RT-PCR. As seen with MMP-9, NTG treat-
ment led to a dose-dependent increase in MMP-2 and
MMP-7 mRNA levels (Fig. 4). Nitroglycerin 200 pmol
increased MMP-2 levels by 135  12% and MMP-7 levels
by 148  12.5% relative to control. Nitroglycerin 2,000
pmol resulted in a more dramatic increase, with MMP-2
levels increased by 187  8% and MMP-7 levels up by
183  21%, p  0.005 and p  0.05, respectively. Im-
portantly, 35 cycles of PCR were required to measure the
mRNA levels of both MMP-2 and -7 compared with only
30 cycles for MMP-9 and TIMP-1. This indicated that
expression of MMP-2 and MMP-7 in human MDMs is
relatively low, as was further demonstrated by an absence of
observable MMP-2 activity using gelatin zymography (Fig. 1).
NTG reduces TIMP-1 protein and mRNA levels in
human MDMs. To determine whether NTG altered ex-
pression of a key TIMP, TIMP-1, TIMP-1 mRNA and
protein levels were measured in human MDMs treated with
NTG 200 pmol and NTG 2,000 pmol. Nitroglycerin
caused a dose-dependent decrease in TIMP-1 mRNA
(200 pmol, 85 1%; 2,000 pmol, 67 7%; p 0.005) and
protein expression (200 pmol, 60  5%; 2,000 pmol, 45 
5%; p  0.005), relative to controls (100  11%; Fig. 5).
DISCUSSION
This study was undertaken to investigate the effects of
NTG, a commonly used drug in the treatment of obstruc-
tive coronary disease, on MMP and TIMP expression in
human macrophages. We found that when MDMs were
exposed to standard pharmacologic doses of NTG, the
agent exerted a striking reciprocal effect on the balance
between MMP and TIMP expression, with MMP-9, -2
and -7 expression enhanced and TIMP-1 expression signif-
icantly inhibited. These changes are consistent with a
pro-inflammatory effect via enhanced matrix degradation.
NTG therapy and mortality in acute coronary syndromes.
Overall, nitrates do not appear to alter outcomes in acute
coronary syndromes, despite their clear benefits in terms of
reducing myocardial preload and dilating coronary arteries
(1). Most early studies of intravenous NTG in this setting
have been small and uncontrolled (23,24) and initially no
randomized controlled trials addressed the efficacy of intra-
venous NTG for symptom relief or control of cardiac events
(25). The recent publications of the large GISSI-3 and
ISIS-4 trials, however, involving more than 75,000 random-
ized patients, clearly show no benefit of oral or transdermal
nitrate therapy on mortality in subjects with acute coronary
syndromes (2,3). This raises the possibility of potentially
deleterious effects of nitrates in this setting, to counterbal-
ance the benefits of coronary dilation. One such possibility
is an adverse effect on plaque stability, via NTG-related
changes in vascular biology.
NTG enhances MMP expression and activity. In this
study, NTG enhanced MMP activity and downregulated
TIMP protein expression, via effects at the mRNA levels.
These opposing effects of NTG on MMP and TIMP
expression effectively amplify the degradation arm of the
MMP/TIMP system, which in turn could lead to net
breakdown of extracellular matrix in atherosclerotic plaques.
Nitroglycerin treatment induced a two- to fourfold increase
in MMP-9 expression and activity. Twofold increases in
MMP activity have been associated with several cardiovas-
cular disease states, including abdominal aortic aneurysm
(26) and dilated cardiomyopathy (27). In a recent study,
raloxifene (a selective estrogen receptor-modulating drug)
was shown to induce a twofold increase in monocyte
Figure 1. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) zymography of media conditioned by human monocyte-
derived macrophages after 24-h exposure to nitroglycerin (NTG). (a) Cells
were exposed for 24 h to glycerol 200 pmol (Lanes 1 and 2) or NTG
200 pmol (Lanes 3 and 4). Aliquots of conditioned media, normalized to
15 g total protein, were run on SDS-PAGE (10%[w/v] gel) supple-
mented with 1 mg/ml gelatin substrate under nonreducing conditions.
Zones of clearing at approximately 90 kDa (as measured by simultaneous
electrophoresis of protein standards, Lane 5) indicate gelatinolytic activity
of both latent (heavier) and active (lighter) matrix metalloproteinase
(MMP)-9. Band densities are: Lanes 1 and 2, glycerol (latent 162,160;
167,492: active 176,945; 173,336) and Lanes 3 and 4, NTG 200 pmol
(latent 29,515; 22,223: active 39,664; 31,960). (b) Aliquots of conditioned
media, normalized to 15 g total protein, were treated with 1 mM
p-aminophenyl mercuric acetate (APMA) for 30 min at 37°C. Treated
samples were then run on SDS-PAGE (10%[w/v] gel) supplemented with
1 mg/ml gelatin substrate under nonreducing conditions. Zones of clearing
at approximately 90 kDa (as measured by simultaneous electrophoresis of
protein standards, Lane 5) indicate gelatinolytic activity of both latent and
active MMP-9. Band densities are Lanes 1 and 2, glycerol (active 269,957;
276,765) and Lanes 3 and 4, NTG 200 pmol (active 321,321; 302,633).
MW  molecular weight.
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MMP-1 production, and patients treated with raloxifene
showed higher peripheral blood monocyte MMP-1 levels;
results interpreted as potentially predisposing to plaque
instability (28). Our current results have shown that NTG
also induces significant basal and recruitable MMP-9 activ-
ity. Although the precise mechanism(s) for the in vivo
activation of MMP-9 is not known, MMP-9 is activated by
plasmin and trypsin, both of which are found in the
atherosclerotic plaque. Thus, increased MMP production
by macrophages induced by NTG treatment may have
important consequences in the most vulnerable regions of
atherosclerotic plaques, where MDMs are known to accu-
mulate preferentially (5).
NTG regulation of MMP gene expression. The signaling
pathways mediating NTG regulation of MMP gene expres-
sion are not completely understood; however, MMP gene
expression occurs under tightly regulated mechanisms that
include changes in transcription (8). Analysis of the MMP/
TIMP promoters has identified essential response elements
including activator protein-1 (AP-1) elements, multiple Ets
elements and, for MMP-9, a nuclear factor-kappa B
(NF-B) element (29). Regulation of MMP or TIMP gene
expression involves interplay between all of the transcription
factors that bind these response elements (30). Nitric
oxide-generating compounds, including SNAP and SIN-1,
have been shown to cause a dose-dependent increase in
NF-B activation in macrophages, which was positively
correlated with the level of NO production (31). Similarly,
NO has been shown to induce AP-1 deoxyribonucleic acid
binding activities in many cell types (32). Thus, the NO
Figure 2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography of media conditioned by human monocyte-derived
macrophages exposed to nitroglycerin (NTG) for 4 h. (a) Cells were exposed for 4 h to control media (Lanes 1 and 2), glycerol (GLY) 200 pmol (Lanes
3 and 4), GLY 2,000 pmol (Lanes 5 and 6), NTG 200 pmol (Lanes 7 and 8), NTG 2,000 pmol (Lanes 9 and 10), 3-morpholinosydnoimine hydrochloride
200 pmol (Lanes 11 and 12) or S-nitroso-N-acetylopenicillamine 200 pmol (Lanes 13 and 14). Aliquots of conditioned media, normalized to 4.5 g total
protein, were run on SDS-PAGE (10%[w/v]gel) supplemented with 1 mg/ml gelatin substrate under nonreducing conditions. Zones of clearing indicate
gelatinolytic activity of latent matrix metalloproteinase (MMP)-9. (b) Scanning analysis of MMP-9 secreted by human MDMs. Results represent the
mean  SEM for analysis of four independent experiments and do not represent the analysis in (a) alone. *p  0.05 compared with control cells. **p 
0.005 compared with control cells. ***p  0.0001 compared to control cells.
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donor, NTG, may regulate MMP and TIMP gene expres-
sion via activation of AP-1 and/or NF-B. This study
showed that not only MMP-9 expression was upregulated
in this study but also two other MMPs were upregulated,
namely MMP-2 and MMP-7. Although the low level of
expression indicates that these findings may not be of
pathophysiologic importance, they demonstrate that NTG
upregulates all measurable MMP expression. It is of impor-
tance that the promoter region of MMP-2 is completely
different to the other MMPs and does not contain AP-1,
Ets or NF-B sites (30). Rather, an AP-2 site predomi-
nantly regulates MMP-2 expression (30). It is not known
whether NTG increases AP-2 deoxyribonucleic acid bind-
Figure 3. The effect of nitroglycerin (NTG) on matrix metalloproteinase (MMP)-9 messenger ribonucleic acid (mRNA) levels in human monocyte-derived
macrophages (MDMs). Cells were exposed to control (CTRL) media (a), NTG 200 pmol (b) or NTG 2,000 pmol (c) for 4 h. Matrix metalloproteinase-9
mRNA levels were measured by competitive reverse transcription-polymerase chain reaction (described in Methods). Competitor mRNA concentrations
were 8.56 (Lane 1), 17.13 (Lane 2), 34.25 (Lane 3), 68.5 (Lane 4) and 137 (Lane 5) attomoles. Arrows represent MMP-9 target (lower band) versus
competitor (upper band) equivalence points for each condition. (d) Quantification of RT-PCR bands was determined by gel densitometry. Results represent
the mean  SEM for analysis of four independent experiments and do not represent the analysis in (a to c) alone. **p  0.005 compared with control cells.
***p  0.001 compared with control cells.
Figure 4. The effect of nitroglycerin (NTG) on matrix metalloproteinase
(MMP)-2 and MMP-7 messenger ribonucleic acid (mRNA) levels in
human monocyte-derived macrophages (MDMs). Cells were exposed to
control media, NTG 200 pmol or NTG 2,000 pmol for 4 h. Total
ribonucleic acid was extracted and competitive reverse transcription-
polymerase chain reaction (RT-PCR) was performed to measure MMP-2
(solid bars) or MMP-7 (open bars) as described in the Methods section,
and each PCR reaction mix was subjected to electrophoresis on a 2% (w/v)
agarose gel. Quantification of RT-PCR bands was determined by gel
densitometry. Results represent the mean  SEM for analysis of three
independent experiments. *p  0.05 and **p  0.005 compared with
control cells.
Figure 5. The effect of nitroglycerin (NTG) on tissue inhibitor of
metalloproteinase (TIMP)-1 expression in human monocyte-derived mac-
rophages. Monocyte-derived macrophages were exposed to control media,
NTG 200 pmol or NTG 2,000 pmol for 4 h. Ribonucleic acid was
extracted and competitive reverse transcription-polymerase chain reaction
performed to measure TIMP-1 messenger ribonucleic acid (mRNA) levels
(solid bars) Y-axis represents mRNA levels as % of control. Aliquots of
conditioned media were collected and TIMP-1 protein levels measured by
enzyme-linked immunosorbent assay (open bars). Y-axis represents pro-
tein concentration (ng/ml). Results represent the mean SEM for analysis
of three independent experiments. **p 0.005 compared with control cells.
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ing activities. Further investigation of the interactions be-
tween these regulatory sites in response to NTG is required
to provide insights into the mechanisms that control NTG
regulation of the MMP/TIMP genes.
NO per se upregulates MMP gene expression. As part of
our investigation, we used three different NO donors,
including two classical direct NO donors, SIN-1 and
SNAP, and one indirect NO donor, NTG, for their
potencies to generate NO and alter MMP/TIMP expres-
sion. All three of the NO donors were effective in altering
MMP/TIMP levels, suggesting it was not the bioactivation
pathway required for NO formation from NTG that led to
the observed effects. Additionally, both NTG and SIN-1,
but not SNAP, treatment can lead to reactive oxygen species
(ROS) formation (superoxide radicals and peroxynitrite).
Nitric oxide then reacts with ROS, and together they are
much more active than either ROS or NO alone in
modifying and changing the expression and functions of
several proteins including MMPs. Indeed, NTG’s effects
depend (in part) on the specific balance between the
concentrations of NO and ROS formation (33,34). Our
finding that all three NO donors in similar concentrations
were similarly effective in altering MMP/TIMP levels is
consistent with the hypothesis that NO per se appears to be
the primary radical inducing the changes in MMP/TIMP
expression in macrophages. It is of interest that Rajagopolan
et al. (11) could not demonstrate that NO stimulated
MMP-2 activity in rabbit lipid-laden macrophages. We
could not measure MMP-2 activity in our cell media after
4- or 24-h incubation times. MMP-9 was by far the
dominant MMP expressed by human macrophages, and the
difference between our results in human cells and the
previous animal study may reflect species differences in
MMP expression.
Study limitations. This investigation suggests that NTG
could increase MDM-derived MMP activity in the athero-
sclerotic plaque. Importantly, the MMP-9 proenzyme is
also constitutively expressed at high levels by monocytes and
macrophages in fatty streaks (35), long before any question
of instability of plaque arises, and thus NTG treatment
leading to activation of MMP-9 may also influence plaque
development. However, whether we can extend our findings
from ex vivo healthy MDMs to those cells harbored in
atherosclerotic plaques remains a limitation of this study.
Although NO donors may have beneficial effects on some
other aspects of vascular biology, such as smooth muscle
relaxation or antiadhesive properties for the endothelium
(36), the current data suggest potentially deleterious effects,
by contrast, as regards MMP production by human macro-
phages.
Summary. In conclusion, NTG in clinically relevant con-
centrations induces MMP, and reduces TIMP-1, expres-
sion by human MDMs. The results reveal a new, heretofore
unappreciated action of nitrates that may need to be
considered when treating CAD. These results suggest the
possibility that MMP inhibition, particularly that targeted
towards MMP-9, may be a novel therapeutic target in the
management of CAD, which frequently requires long-term
administration of NTG. In addition, the vascular biological
observations in this study may help explain the lack of a
positive association between NTG therapy and beneficial
effects on plaque progression or coronary event rates, despite
NTG’s powerful vasodilator activity.
Reprint requests and correspondence: Prof. David S. Celerma-
jer, Department of Cardiology, Royal Prince Alfred Hospital,
Missendon Road, Camperdown Sydney, NSW 2050, Australia.
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